Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction- associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial

Año publicación: 2025

Subir documento: https://drive.google.com/file/d/1ZGlknIIn8niUD1R5c32rZHwES6141JJ7/view?usp=sharing

Nombre investigadores: Rohit Loomba, Kris V Kowdley, Jose Rodriguez, Nomita J Kim, Alina Maria Alvarez, Linda Morrow, Brenda Jeglinski, Alicia Clawson, Swapan Chowdhury, Gerard Bain, Tatjana Odrljin